Drug Patents owned by Allergan

1. Drug name - ACULAR LS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8008338 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
May, 2027

(4 years from now)

EP3217937A4 ALLERGAN Bed Systems And Methods
Nov, 2035

(13 years from now)

EP3217937A1 ALLERGAN Bed Systems
Nov, 2035

(13 years from now)

EP3217937B1 ALLERGAN Bed Systems
Nov, 2035

(13 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8946281 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain May, 2024

(1 year, 7 months from now)

US8906950 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain May, 2024

(1 year, 7 months from now)

US8648107 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain May, 2024

(1 year, 7 months from now)

US8541463 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain May, 2024

(1 year, 7 months from now)

US9216167 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain May, 2024

(1 year, 7 months from now)

US8377982 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain May, 2024

(1 year, 7 months from now)

US8207215 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain May, 2024

(1 year, 7 months from now)

US8541463

(Pediatric)

ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain Nov, 2024

(2 years from now)

US8207215

(Pediatric)

ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain Nov, 2024

(2 years from now)

US8377982

(Pediatric)

ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain Nov, 2024

(2 years from now)

US8008338

(Pediatric)

ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain Nov, 2027

(5 years from now)

Drugs and Companies using KETOROLAC TROMETHAMINE ingredient

Treatment: A method of treating ocular pain; A method of treating or preventing ocular pain and burning; A method of treating or reducing ocular pain and burning/stinging; A method of treating ocular pain and/or enhancing ocular comfort; A method of treating or preventing ocular pain and burning/stinging following corneal surgery; A method of controlling postoperative ocular pain and burning/stinging in a patient

Dosage: SOLUTION/DROPS;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
0.4% SOLUTION/DROPS;OPHTHALMIC Prescription

2. Drug name - ACUVAIL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7842714 ALLERGAN Ketorolac tromethamine compositions for treating ocular pain
Aug, 2029

(6 years from now)

CN102014869A ALLERGAN Ketorolac Tromethamine Compositions For Treating Or Preventing Ocular Pain
Sep, 2015

(7 years ago)

CN103976943A ALLERGAN Ketorolac Tromethamine Compositions For Treating Or Preventing Ocular Pain
Mar, 2029

(6 years from now)

CN103976943B ALLERGAN Ketorolac Tromethamine Compositions For Treating Or Preventing Ocular Pain
Mar, 2029

(6 years from now)

CN102497856A ALLERGAN Ketorolac Tromethamine Composition For Treating Or Preventing Eye Pain
Aug, 2030

(7 years from now)

CN102497856B ALLERGAN For Treating Or Prevention Eye Pain Of Ketorolac Tromethamine Composition
Aug, 2030

(7 years from now)

IN201006461P1 ALLERGAN Ketorolac Tromethamine Compositions For Treating Or Preventing Ocular Pain
Mar, 2029

(6 years from now)

IN286644B ALLERGAN Ketorolac Tromethamine Compositions For Treating Or Preventing Ocular Pain
Mar, 2029

(6 years from now)

EP2257275A2 ALLERGAN Ketorolac Tromethamine Compositions For Treating Or Preventing Ocular Pain
Mar, 2029

(6 years from now)

EP2446878A1 ALLERGAN Ketorolac Tromethamine Compositions For Treating Or Preventing Ocular Pain
Mar, 2029

(6 years from now)

EP2257275B1 ALLERGAN Ketorolac Tromethamine Compositions For Treating Or Preventing Ocular Pain
Mar, 2029

(6 years from now)

EP2446878B1 ALLERGAN Ketorolac Tromethamine Compositions For Treating Or Preventing Ocular Pain
Mar, 2029

(6 years from now)

EP2473157B1 ALLERGAN Ketorolac Tromethamine Compositions For Treating Or Preventing Ocular Pain
Aug, 2030

(7 years from now)

EP2473157A1 ALLERGAN Ketorolac Tromethamine Compositions For Treating Or Preventing Ocular Pain
Aug, 2030

(7 years from now)

EP2555770B1 ALLERGAN Ketorolac Compositions For Corneal Wound Healing
Apr, 2031

(8 years from now)

EP2555770A1 ALLERGAN Ketorolac Compositions For Corneal Wound Healing
Apr, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8992952 ALLERGAN Compositions for delivery of therapeutics into the eyes and methods for making and using same Aug, 2024

(1 year, 10 months from now)

US8512717 ALLERGAN Compositions for delivery of therapeutics into the eyes and methods for making and using same Mar, 2028

(5 years from now)

US9192571 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain Mar, 2028

(5 years from now)

Drugs and Companies using KETOROLAC TROMETHAMINE ingredient

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
0.45% SOLUTION/DROPS;OPHTHALMIC Prescription

3. Drug name - ALPHAGAN P

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8858961 ALLERGAN Compositions containing alpha-2-adrenergic agonist components Sep, 2023

(11 months from now)

US8858961

(Pediatric)

ALLERGAN Compositions containing alpha-2-adrenergic agonist components Mar, 2024

(1 year, 5 months from now)

Drugs and Companies using BRIMONIDINE TARTRATE ingredient

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
0.1% SOLUTION/DROPS;OPHTHALMIC Prescription

4. Drug name - AVYCAZ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7112592 ALLERGAN Azabicyclic compounds, preparation thereof and use as medicines, in particular as antibacterial agents
Jan, 2026

(3 years from now)

US8471025 ALLERGAN Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt
Aug, 2031

(8 years from now)

US8969566 ALLERGAN Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
Jun, 2032

(9 years from now)

US9695122 ALLERGAN Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
Jun, 2032

(9 years from now)

US9284314 ALLERGAN Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
Jun, 2032

(9 years from now)

CN104592229A ALLERGAN Polymorphic Form And False Polymorphic Form Of Medicine Composition
Aug, 2019

(3 years ago)

CN1289500C ALLERGAN Nitrogen Heterocyclic Ring Compounds, Their Preparation Method And Their Application As Medicine, Especially Application As Antibacterial Agent
Jul, 2021

(1 year, 2 months ago)

CN1468242A ALLERGAN Nitrogen Heterocyclic Ring Compounds, Their Preparation Method And Their Application As Medicine, Especially Application As Antibacterial Agent
Jul, 2021

(1 year, 2 months ago)

CN102834395B ALLERGAN Polymorphic Form And False Polymorphic Form Of Medicine Composition
Oct, 2030

(8 years from now)

CN102834395A ALLERGAN Polymorphic Form And False Polymorphic Form Of Medicine Composition
Oct, 2030

(8 years from now)

CN105294690A ALLERGAN The Preparation Comprises -7 - Oxo -6-(Sulfo-Oxy) -1, 6-Diazabicyclo [3 2 1] Octane - -2 - Formamide Heterocyclic Compound And Salt Thereof
Jun, 2032

(9 years from now)

CN103649051A ALLERGAN Method For Preparing Heterocyclic Compound Comprising Reverse-7-Oxo- -6-(Sulfo Group) -1, 6-Two [3, 2, 1] -2 -Carboxamide And The Salt Thereof
Jun, 2032

(9 years from now)

CN105294690B ALLERGAN Preparation Comprising Anti - -7 - Oxo - -6-(Sulfo Group) -1, 6-Di-Aza-Bicyclo (3, 2, 1] -2 - Formamide Heterocyclic Compound And Its Salt Method
Jun, 2032

(9 years from now)

CN103649051B ALLERGAN Method For Preparing Heterocyclic Compound Comprising Reverse-7-Oxo- -6-(Sulfo Group) -1, 6-Two [3, 2, 1] -2 -Carboxamide And The Salt Thereof
Jun, 2032

(9 years from now)

IN248632B ALLERGAN Azabicyclic Heterocyclic Compound
Jul, 2021

(1 year, 2 months ago)

IN238630B ALLERGAN Process For The Preparation Of A Heterocyclic Compound
Jul, 2021

(1 year, 2 months ago)

IN200503239P1 ALLERGAN Compound Of General Formula (I) Or One Its Salts With A Base Or An Acid
Jul, 2021

(1 year, 2 months ago)

IN200300268P1 ALLERGAN Azabicyclic Compounds, Preparation Thereof And Use As Medicines, In Particular As Antibacterial Agents
Jul, 2021

(1 year, 2 months ago)

EP1307457B1 ALLERGAN Azabicyclic Compounds, Preparation Thereof And Use As Medicines, In Particular As Antibacterial Agents
Jul, 2021

(1 year, 2 months ago)

EP1307457A1 ALLERGAN Azabicyclic Compounds, Preparation Thereof And Use As Medicines, In Particular As Antibacterial Agents
Jul, 2021

(1 year, 2 months ago)

EP3269717A1 ALLERGAN Polymorphic And Pseudopolymorphic Forms Of Pharmaceutical Compound Nxl104
Oct, 2030

(8 years from now)

EP3269717B1 ALLERGAN Polymorphic And Pseudopolymorphic Forms Of Pharmaceutical Compound Nxl104
Oct, 2030

(8 years from now)

EP2486038B1 ALLERGAN Polymorphic And Pseudopolymorphic Forms Of A Pharmaceutical Compound
Oct, 2030

(8 years from now)

EP2486038A1 ALLERGAN Polymorphic And Pseudopolymorphic Forms Of A Pharmaceutical Compound
Oct, 2030

(8 years from now)

EP2721005B1 ALLERGAN Process For Preparing Heterocyclic Compounds Including Trans-7-Oxo-6-(Sulphooxy)-1,6-Diazabicyclo[3,2,1]Octane-2-Carboxamide And Salts Thereof
Jun, 2032

(9 years from now)

EP2721005A1 ALLERGAN Process For Preparing Heterocyclic Compounds Including Trans-7-Oxo-6-(Sulphooxy)-1,6-Diazabicyclo[3,2,1]Octane-2-Carboxamide And Salts Thereof
Jun, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7612087 ALLERGAN Heterocyclic compounds as inhibitors of beta-lactamases Nov, 2026

(4 years from now)

US8835455 ALLERGAN Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt Oct, 2030

(8 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 0.5GM BASE;2GM/VIAL POWDER;INTRAVENOUS Prescription

5. Drug name - BYVALSON

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7803838 ALLERGAN Compositions comprising nebivolol Aug, 2026

(3 years from now)

US7838552 ALLERGAN Compositions comprising nebivolol Oct, 2027

(5 years from now)

Drugs and Companies using NEBIVOLOL HYDROCHLORIDE; VALSARTAN ingredient

Treatment: Method of treating hypertension

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 5MG BASE;80MG TABLET;ORAL Discontinued

6. Drug name - CANASA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8217083 ALLERGAN Mesalamine suppository Jun, 2028

(5 years from now)

US8436051 ALLERGAN Mesalamine suppository Jun, 2028

(5 years from now)

Drugs and Companies using MESALAMINE ingredient

Treatment: NA

Dosage: SUPPOSITORY;RECTAL

More Information on Dosage
Strength Dosage Availability
1GM SUPPOSITORY;RECTAL Prescription
500MG SUPPOSITORY;RECTAL Discontinued

7. Drug name - COMBIGAN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7642258 ALLERGAN Combination of brimonidine and timolol for topical ophthalmic use
Apr, 2022

(5 months ago)

CN101664414A ALLERGAN Combination Of Brimonidine And Timolol For Topical Ophthalmic Use
Jan, 2013

(9 years ago)

CN112219061A ALLERGAN Suspension Type Vertical Decoration Light Guide Lamp With Sound Suppression
Jan, 2022

(8 months ago)

CN1516588A ALLERGAN Combination Of Brimonidine And Timolol For Topical Ophthalmic Use
Apr, 2023

(6 months from now)

CN100558364C ALLERGAN Combination Of Brimonidine And Timolol For Topical Ophthalmic Use
Apr, 2023

(6 months from now)

EP1496912B1 ALLERGAN Combination Of Brimonidine And Timolol For Topical Ophthalmic Use
Apr, 2023

(6 months from now)

EP1496912A1 ALLERGAN Combination Of Brimonidine And Timolol For Topical Ophthalmic Use
Apr, 2023

(6 months from now)

EP1496912B9 ALLERGAN Combination Of Brimonidine And Timolol For Topical Ophthalmic Use
Apr, 2023

(6 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7323463 ALLERGAN Combination of brimonidine and timolol for topical ophthalmic use Jan, 2023

(3 months from now)

More Information on Dosage
Strength Dosage Availability
0.2%;EQ 0.5% BASE SOLUTION/DROPS;OPHTHALMIC Prescription

8. Drug name - DALVANCE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7115564 ALLERGAN Stable pharmaceutical compositions of dalbavancin and methods of administration Nov, 2023

(1 year, 1 month from now)

US8143212 ALLERGAN Dalbavancin compositions for treatment of bacterial infections Nov, 2023

(1 year, 1 month from now)

US7119061 ALLERGAN Dalbavancin compositions for treatment of bacterial infections Nov, 2023

(1 year, 1 month from now)

US6900175 ALLERGAN Methods of administering dalbavancin for treatment of bacterial infections Dec, 2023

(1 year, 2 months from now)

Drugs and Companies using DALBAVANCIN HYDROCHLORIDE ingredient

Treatment: Treatment of bacterial infections using a two-dose regimen of dalbavancin.

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
EQ 500MG BASE/VIAL POWDER;INTRAVENOUS Prescription

9. Drug name - FETZIMA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8865937 ALLERGAN Crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide
May, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE43879 ALLERGAN Use of the dextrogyral enantiomer of milnacipran for the preparation of a drug Jan, 2026

(3 years from now)

US8481598 ALLERGAN Stable dosage forms of levomilnacipran Mar, 2031

(8 years from now)

Drugs and Companies using LEVOMILNACIPRAN HYDROCHLORIDE ingredient

Treatment: Treatment of major depressive disorder (mdd)

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 20MG BASE CAPSULE, EXTENDED RELEASE;ORAL Prescription
EQ 40MG BASE CAPSULE, EXTENDED RELEASE;ORAL Prescription
EQ 80MG BASE CAPSULE, EXTENDED RELEASE;ORAL Prescription
EQ 120MG BASE CAPSULE, EXTENDED RELEASE;ORAL Prescription

10. Drug name - GELNIQUE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9259388 ALLERGAN Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions Nov, 2029

(7 years from now)

US10449173 ALLERGAN Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions Nov, 2029

(7 years from now)

US8920392 ALLERGAN Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions Mar, 2031

(8 years from now)

Drugs and Companies using OXYBUTYNIN CHLORIDE ingredient

Treatment: Treatment of overactive bladder by application of oxybutynin chloride gel to skin; Treatment of patients with an overactive bladder with symptoms of urinary frequency, urgency, or urge incontinence with a single unit dose of 10% oxybutynin chloride gel

Dosage: GEL;TRANSDERMAL

More Information on Dosage
Strength Dosage Availability
10% (100MG/PACKET) GEL;TRANSDERMAL Prescription

11. Drug name - LASTACAFT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10617695 ALLERGAN Ophthalmic compositions containing alcaftadine Mar, 2027

(4 years from now)

US8664215 ALLERGAN Ocular allergy treatments with alcaftadine Dec, 2027

(5 years from now)

Drugs and Companies using ALCAFTADINE ingredient

Treatment: Use of lastacaft to temporary relieve itchy eyes due to pollen, ragweed, grass, animal hair and dander

Dosage: SOLUTION/DROPS;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
0.25% SOLUTION/DROPS;OPHTHALMIC Over the counter

12. Drug name - LATISSE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8038988 ALLERGAN Method of enhancing hair growth
Aug, 2023

(10 months from now)

EP2802331A1 ALLERGAN Topical Treatment For Chemotherapy Induced Eyelash Loss Or Hypotrichosis Using Prostamide F2 Alpha Agonists
Jan, 2033

(10 years from now)

EP2802331B1 ALLERGAN Topical Treatment For Chemotherapy Induced Eyelash Loss Or Hypotrichosis Using Prostamide F2 Alpha Agonists
Jan, 2033

(10 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8986715 ALLERGAN Method of enhancing hair growth Jan, 2023

(3 months from now)

US8632760 ALLERGAN Method of enhancing hair growth Jan, 2023

(3 months from now)

US9216183 ALLERGAN Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists Jan, 2023

(3 months from now)

US8758733 ALLERGAN Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists Jan, 2023

(3 months from now)

US9226931 ALLERGAN Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists Jan, 2023

(3 months from now)

US8263054 ALLERGAN Method of enhancing hair growth Jan, 2023

(3 months from now)

US8101161 ALLERGAN Method of enhancing hair growth May, 2024

(1 year, 7 months from now)

Drugs and Companies using BIMATOPROST ingredient

Treatment: Method of increasing hair growth; Method of increasing eyelash growth; Method of increasing growth of hair including eyelashes; Method of increasing eyelash growth including length, thickness, darkness and/or number of eyelashes by administering bimatoprost to an eyelid margin; Method of stimulating hair growth; method of increasing hair growth

Dosage: SOLUTION/DROPS;TOPICAL

More Information on Dosage
Strength Dosage Availability
0.03% SOLUTION/DROPS;TOPICAL Prescription

13. Drug name - LEXAPRO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6916941 ALLERGAN Crystalline composition containing escitalopram
Aug, 2022

(a month ago)

CN1660074A ALLERGAN Crystalline Composition Containing Escitalopram
Oct, 2007

(15 years ago)

CN1311819C ALLERGAN Crystalline Composition Containing Escitalopram
Jul, 2022

(2 months ago)

CN1536997A ALLERGAN Crystalline Composition Containing Escitalopram
Jul, 2022

(2 months ago)

IN227935B ALLERGAN A Method For Manufacture Of Crystalline Particles Of Escitalpram Oxalate
Jul, 2022

(2 months ago)

IN200400405P4 ALLERGAN Crystalline Composition Containing Escitalopram
Jul, 2022

(2 months ago)

EP1522539A1 ALLERGAN Crystalline Composition Containing Escitalopram
Sep, 2010

(12 years ago)

EP1522539B1 ALLERGAN Crystalline Composition Containing Escitalopram
Sep, 2010

(12 years ago)

EP1414435B1 ALLERGAN Crystalline Composition Containing Escitalopram
Jul, 2022

(2 months ago)

EP1414435A1 ALLERGAN Crystalline Composition Containing Escitalopram
Jul, 2022

(2 months ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6916941

(Pediatric)

ALLERGAN Crystalline composition containing escitalopram Feb, 2023

(4 months from now)

US7420069

(Pediatric)

ALLERGAN Crystalline composition containing escitalopram Feb, 2023

(4 months from now)

More Information on Dosage
Strength Dosage Availability
EQ 5MG BASE TABLET;ORAL Prescription
EQ 10MG BASE TABLET;ORAL Prescription
EQ 20MG BASE TABLET;ORAL Prescription

14. Drug name - LINZESS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7704947 ALLERGAN Methods and compositions for the treatment of gastrointestinal disorders
Jan, 2024

(1 year, 3 months from now)

US8080526 ALLERGAN Methods and compositions for the treatment of gastrointestinal disorders
Jan, 2024

(1 year, 3 months from now)

US7371727 ALLERGAN Methods and compositions for the treatment of gastrointestinal disorders
Jan, 2024

(1 year, 3 months from now)

US7745409 ALLERGAN Methods and compositions for the treatment of gastrointestinal disorders
Jan, 2024

(1 year, 3 months from now)

US7304036 ALLERGAN Methods and compositions for the treatment of gastrointestinal disorders
Aug, 2026

(3 years from now)

CN101010335A ALLERGAN The Method And Combination For Curing The Gastrointestinal Disease
Sep, 2011

(11 years ago)

CN102020704A ALLERGAN Method And Composition For The Treatment Of Gastrointestinal Disorders
Apr, 2013

(9 years ago)

CN101787073A ALLERGAN Method And Composition For The Treatment Of Gastrointestinal Disorders
Jan, 2024

(1 year, 3 months from now)

CN101787073B ALLERGAN Methods And Compositions For The Treatment Of Gastrointestinal Disorders
Jan, 2024

(1 year, 3 months from now)

CN1795007A ALLERGAN Method And Composition For The Treatment Of Gastrointestinal Disorders
Jan, 2024

(1 year, 3 months from now)

CN100589839C ALLERGAN Polypeptide And A Pharmaceutical Composition Comprising The Polypeptide
Jan, 2024

(1 year, 3 months from now)

IN200503394P1 ALLERGAN Methods And Compositions For The Treatment Of Gastrointestinal Disorders
Jan, 2024

(1 year, 3 months from now)

IN237521B ALLERGAN A Purified Peptide Which Activates The Guanylate Cyclase C Receptor For Use In Gastrointestinal Disorders
Jan, 2024

(1 year, 3 months from now)

EP1911763B1 ALLERGAN Compositions For The Treatment Of Gastrointestinal Disorders
Jan, 2024

(1 year, 3 months from now)

EP1911763A2 ALLERGAN Compositions For The Treatment Of Gastrointestinal Disorders
Jan, 2024

(1 year, 3 months from now)

EP1911763A3 ALLERGAN Compositions For The Treatment Of Gastrointestinal Disorders
Jan, 2024

(1 year, 3 months from now)

EP2088154B1 ALLERGAN Methods And Compositions For The Treatment Of Gastrointestinal Disorders
Mar, 2025

(2 years from now)

EP2088154A1 ALLERGAN Methods And Compositions For The Treatment Of Gastrointestinal Disorders
Mar, 2025

(2 years from now)

EP2246360A1 ALLERGAN Compositions For The Treatment Of Gastrointestinal Disorders
Nov, 2027

(5 years from now)

EP2246360B1 ALLERGAN Compositions For The Treatment Of Gastrointestinal Disorders
Nov, 2027

(5 years from now)

EP1594517A4 ALLERGAN Methods And Compositions For The Treatment Of Gastrointestinal Disorders
Nov, 2027

(5 years from now)

EP1594517B1 ALLERGAN Compositions For The Treatment Of Gastrointestinal Disorders
Nov, 2027

(5 years from now)

EP1594517A2 ALLERGAN Compositions For The Treatment Of Gastrointestinal Disorders
Nov, 2027

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8110553 ALLERGAN Methods and compositions for the treatment of gastrointestinal disorders Jan, 2024

(1 year, 3 months from now)

US8933030 ALLERGAN Treatments for gastrointestinal disorders Feb, 2031

(8 years from now)

US10702576 ALLERGAN Stable formulations of linaclotide Aug, 2031

(8 years from now)

US10675325 ALLERGAN Stable formulations of linaclotide Aug, 2031

(8 years from now)

US8748573 ALLERGAN Formulations comprising linaclotide Oct, 2031

(9 years from now)

US8802628 ALLERGAN Stable solid formulation of a GC-C receptor agonist polypeptide suitable for oral administration Oct, 2031

(9 years from now)

US9708371 ALLERGAN Treatments for gastrointestinal disorders Aug, 2033

(10 years from now)

Drugs and Companies using LINACLOTIDE ingredient

Treatment: Method of treating chronic idiopathic constipation in adult patients.; method of treating irritable bowel syndrome with constipation in adults; Method of treating chronic idiopathic constipation in adult patients.; Method of treating chronic idiopathic constipation in adult patients.; method of treating irritable bowel syndrome with constipation in adult patients.; Method of treating irritable bowel syndrome with constipation in adult patients.; method of treating chronic idiopathic constipation in adult patients.

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
72MCG CAPSULE;ORAL Prescription
145MCG CAPSULE;ORAL Prescription
290MCG CAPSULE;ORAL Prescription

15. Drug name - LUMIGAN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7851504 ALLERGAN Enhanced bimatoprost ophthalmic solution
Jun, 2027

(4 years from now)

CN101137383A ALLERGAN Enhanced Bimatoprost Ophthalmic Solution
Mar, 2026

(3 years from now)

CN102240292A ALLERGAN Enhanced Bimatoprost Ophthalmic Solution
Mar, 2026

(3 years from now)

CN101137383B ALLERGAN Enhanced Bimatoprost Ophthalmic Solution
Mar, 2026

(3 years from now)

CN102240292B ALLERGAN Enhanced Bimatoprost Ophthalmic Solution
Mar, 2026

(3 years from now)

IN263623B ALLERGAN Enhanced Bimatoprost Ophthalmic Solution
Mar, 2026

(3 years from now)

IN200706652P1 ALLERGAN Enhanced Bimatoprost Opthalmic Solution
Mar, 2026

(3 years from now)

EP1753434A2 ALLERGAN Enhanced Bimatoprost Ophthalmic Solution
Mar, 2026

(3 years from now)

EP1753434B1 ALLERGAN Enhanced Bimatoprost Ophthalmic Solution
Mar, 2026

(3 years from now)

EP1753434B2 ALLERGAN Enhanced Bimatoprost Ophthalmic Solution
Mar, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9155716 ALLERGAN Enhanced bimatoprost ophthalmic solution Mar, 2025

(2 years from now)

US8524777 ALLERGAN Enhanced bimatoprost ophthalmic solution Mar, 2025

(2 years from now)

US8338479 ALLERGAN Enhanced bimatoprost ophthalmic solution Mar, 2025

(2 years from now)

US8772338 ALLERGAN Enhanced bimatoprost ophthalmic solution Mar, 2025

(2 years from now)

US8299118 ALLERGAN Enhanced bimatoprost ophthalmic solution Mar, 2025

(2 years from now)

US9241918 ALLERGAN Enhanced bimatoprost ophthalmic solution Mar, 2025

(2 years from now)

US8933120 ALLERGAN Enhanced bimatoprost ophthalmic solution Mar, 2025

(2 years from now)

US8933127 ALLERGAN Enhanced bimatoprost ophthalmic solution Mar, 2025

(2 years from now)

US8278353 ALLERGAN Enhanced bimatoprost ophthalmic solution Mar, 2025

(2 years from now)

US8309605 ALLERGAN Enhanced bimatoprost ophthalmic solution Mar, 2025

(2 years from now)

US8586630 ALLERGAN Enhanced bimatoprost ophthalmic solution Mar, 2025

(2 years from now)

Drugs and Companies using BIMATOPROST ingredient

Treatment: A method of lowering intraocular pressure; Reduction of elevated intraocular pressure in patients with glaucoma or ocular hypertension; A method of treating a patient with glaucoma or ocular hypertension; Method of treating glaucoma or elevated intraocular pressure; A method of lowering intraocular pressure in a patient with open angle glaucoma or ocular hypertension; method of treating glaucoma in a patient; A method of reducing intraocular pressure in patients with open angle glaucoma or ocular hypertension

Dosage: SOLUTION/DROPS;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
0.01% SOLUTION/DROPS;OPHTHALMIC Prescription

16. Drug name - NAMENDA XR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8039009 ALLERGAN Modified release formulations of memantine oral dosage forms Mar, 2029

(6 years from now)

US8039009

(Pediatric)

ALLERGAN Modified release formulations of memantine oral dosage forms Sep, 2029

(6 years from now)

Drugs and Companies using MEMANTINE HYDROCHLORIDE ingredient

Treatment: Treatment of moderate to severe dementia of the alzheimer's type

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
7MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
14MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
21MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
28MG CAPSULE, EXTENDED RELEASE;ORAL Prescription

17. Drug name - NAMZARIC

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8580858 ALLERGAN Compositions for the treatment of CNS-related conditions Nov, 2025

(3 years from now)

US8168209 ALLERGAN Method and composition for administering an NMDA receptor antagonist to a subject Nov, 2025

(3 years from now)

US8598233 ALLERGAN Method for administering an NMDA receptor antagonist to a subject Nov, 2025

(3 years from now)

US8338485 ALLERGAN Compositions for the treatment of CNS-related conditions Nov, 2025

(3 years from now)

US8173708 ALLERGAN Method and composition for administering an NMDA receptor antagonist to a subject Nov, 2025

(3 years from now)

US8362085 ALLERGAN Method for administering an NMDA receptor antagonist to a subject Nov, 2025

(3 years from now)

US8293794 ALLERGAN Methods and compositions for the treatment of CNS-related conditions Nov, 2025

(3 years from now)

US8338486 ALLERGAN Methods for the treatment of CNS-related conditions Nov, 2025

(3 years from now)

US8283379 ALLERGAN Methods and compositions for the treatment of CNS-related conditions Nov, 2025

(3 years from now)

US8329752 ALLERGAN Composition for administering an NMDA receptor antagonist to a subject Nov, 2025

(3 years from now)

US8598233

(Pediatric)

ALLERGAN Method for administering an NMDA receptor antagonist to a subject May, 2026

(3 years from now)

US8362085

(Pediatric)

ALLERGAN Method for administering an NMDA receptor antagonist to a subject May, 2026

(3 years from now)

US8173708

(Pediatric)

ALLERGAN Method and composition for administering an NMDA receptor antagonist to a subject May, 2026

(3 years from now)

US8168209

(Pediatric)

ALLERGAN Method and composition for administering an NMDA receptor antagonist to a subject May, 2026

(3 years from now)

US8283379

(Pediatric)

ALLERGAN Methods and compositions for the treatment of CNS-related conditions May, 2026

(3 years from now)

US8329752

(Pediatric)

ALLERGAN Composition for administering an NMDA receptor antagonist to a subject May, 2026

(3 years from now)

US8039009 ALLERGAN Modified release formulations of memantine oral dosage forms Mar, 2029

(6 years from now)

US8039009

(Pediatric)

ALLERGAN Modified release formulations of memantine oral dosage forms Sep, 2029

(6 years from now)

US8058291 ALLERGAN Methods and compositions for the treatment of CNS-related conditions Dec, 2029

(7 years from now)

Drugs and Companies using DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE ingredient

Treatment: Memantine hcl/donepezil hcl combination for the treatment of moderate to severe dementia of the alzheimer's type

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
10MG;7MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
10MG;14MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
10MG;21MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
10MG;28MG CAPSULE, EXTENDED RELEASE;ORAL Prescription

18. Drug name - OZURDEX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10702539 ALLERGAN Ocular implant made by a double extrusion process Jan, 2023

(3 months from now)

US8506987 ALLERGAN Ocular implant made by a double extrusion process Jan, 2023

(3 months from now)

US8034366 ALLERGAN Ocular implant made by a double extrusion process Jan, 2023

(3 months from now)

US8034370 ALLERGAN Ocular implant made by a double extrusion process Jan, 2023

(3 months from now)

US10076526 ALLERGAN Ocular implant made by a double extrusion process Jan, 2023

(3 months from now)

US9192511 ALLERGAN Ocular implant made by a double extrusion process Jan, 2023

(3 months from now)

US6899717 ALLERGAN Methods and apparatus for delivery of ocular implants Nov, 2023

(1 year, 1 month from now)

Drugs and Companies using DEXAMETHASONE ingredient

Treatment: Treatment of diabetic macular edema; treatment of macular edema following branch retinal vein occlusion (brvo) or central retinal vein occlusion (crvo); treatment of non-infectious uveitis affecting the posterior segment of the eye; Treatment of macular edema; treatment of uveitis; Delivering an ocular implant as described in the dosage and administration section of the approved labeling of ozurdex

Dosage: IMPLANT;INTRAVITREAL

More Information on Dosage
Strength Dosage Availability
0.7MG IMPLANT;INTRAVITREAL Prescription

19. Drug name - RESTASIS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9248191 ALLERGAN Methods of providing therapeutic effects using cyclosporin components Aug, 2024

(1 year, 10 months from now)

US8633162 ALLERGAN Methods of providing therapeutic effects using cyclosporin components Aug, 2024

(1 year, 10 months from now)

US8629111 ALLERGAN Methods of providing therapeutic effects using cyclosporin components Aug, 2024

(1 year, 10 months from now)

US8648048 ALLERGAN Methods of providing therapeutic effects using cyclosporin components Aug, 2024

(1 year, 10 months from now)

US8642556 ALLERGAN Methods of providing therapeutic effects using cyclosporin components Aug, 2024

(1 year, 10 months from now)

US8685930 ALLERGAN Methods of providing therapeutic effects using cyclosporin components Aug, 2024

(1 year, 10 months from now)

US8292129 ALLERGAN Dispensing device Feb, 2031

(8 years from now)

US8561859 ALLERGAN Dispensing device Apr, 2032

(9 years from now)

US9676525 ALLERGAN Protective cap for a dispenser, and discharge device for discharging pharmaceutical and/or cosmetical liquids Feb, 2034

(11 years from now)

US9669974 ALLERGAN Protective cap for a dispenser, and discharge device for discharging pharmaceutical and/or cosmetical liquids May, 2034

(11 years from now)

Drugs and Companies using CYCLOSPORINE ingredient

Treatment: Increase tear production to treat patients with keratoconjunctivitis sicca (dry eye).; Increase tear production in patients with keratoconjunctivitis sicca (dry eye).

Dosage: EMULSION;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
0.05% EMULSION;OPHTHALMIC Prescription

20. Drug name - SAPHRIS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7741358 ALLERGAN Crystal form of asenapine maleate
Apr, 2026

(3 years from now)

US8022228 ALLERGAN Crystal form of asenapine maleate
Apr, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8022228

(Pediatric)

ALLERGAN Crystal form of asenapine maleate Oct, 2026

(4 years from now)

US7741358

(Pediatric)

ALLERGAN Crystal form of asenapine maleate Oct, 2026

(4 years from now)

Drugs and Companies using ASENAPINE MALEATE ingredient

Treatment: NA

Dosage: TABLET;SUBLINGUAL

More Information on Dosage
Strength Dosage Availability
EQ 2.5MG BASE TABLET;SUBLINGUAL Prescription
EQ 5MG BASE TABLET;SUBLINGUAL Prescription
EQ 10MG BASE TABLET;SUBLINGUAL Prescription

21. Drug name - SAVELLA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6602911 ALLERGAN Methods of treating fibromyalgia Jan, 2023

(3 months from now)

US7994220 ALLERGAN Milnacipran for the long-term treatment of fibromyalgia syndrome Sep, 2029

(6 years from now)

Drugs and Companies using MILNACIPRAN HYDROCHLORIDE ingredient

Treatment: Management of fibromyalgia (fm); Management of fibromyalgia

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
12.5MG TABLET;ORAL Prescription
25MG TABLET;ORAL Prescription
50MG TABLET;ORAL Prescription
100MG TABLET;ORAL Prescription

22. Drug name - TEFLARO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6417175 ALLERGAN Phosphonocephem derivatives, process for the preparation of the same, and use thereof
Apr, 2022

(5 months ago)

CN1194980C ALLERGAN Phosphoryl Derivatives, Their Preparation And Use
Dec, 2018

(3 years ago)

CN1679595B ALLERGAN Phosphonoalkane Derivatives, Their Preparation And Use
Dec, 2018

(3 years ago)

CN1282335A ALLERGAN Phosphoryl Derivatives, Their Preparation And Use
Dec, 2018

(3 years ago)

CN1679595A ALLERGAN Phosphoryl Derivatives, Their Preparation And Use
Dec, 2018

(3 years ago)

EP1043327A4 ALLERGAN Phosphonocephem Derivatives, Process For The Preparation Of The Same, And Use Thereof
Dec, 2023

(1 year, 2 months from now)

EP1043327A1 ALLERGAN Phosphonocephem Derivatives, Process For The Preparation Of The Same, And Use Thereof
Dec, 2023

(1 year, 2 months from now)

EP1043327B1 ALLERGAN Phosphonocephem Derivatives, Process For The Preparation Of The Same, And Use Thereof
Dec, 2023

(1 year, 2 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9629861 ALLERGAN Compositions and methods for treating bacterial infections using ceftaroline Sep, 2030

(7 years from now)

US8247400 ALLERGAN Cephem compounds useful for the treatment of bacterial infections Feb, 2031

(8 years from now)

Drugs and Companies using CEFTAROLINE FOSAMIL ingredient

Treatment: Method of treating bacterial infections

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
400MG/VIAL POWDER;INTRAVENOUS Prescription
600MG/VIAL POWDER;INTRAVENOUS Prescription

23. Drug name - UBRELVY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9499545 ALLERGAN Piperidinone carboxamide azaindane CGRP receptor antagonists
Nov, 2031

(9 years from now)

US8912210 ALLERGAN Piperidinone carboxamide azaindane CGRP receptor antagonists
Nov, 2031

(9 years from now)

US8754096 ALLERGAN Piperidinone carboxamide azaindane CGRP receptor antagonists
Jul, 2032

(9 years from now)

CN103328478A ALLERGAN Piperidones Carboxamide Indane Cgrp Receptor Antagonist
Nov, 2031

(9 years from now)

CN103328478B ALLERGAN Piperidone Carboxamide Nitrogen Mixed Indene Into Cgrp Receptor Antagonists
Nov, 2031

(9 years from now)

IN201303390P4 ALLERGAN Piperidinone Carboxamide Azaindane Cgrp Receptor Antagonists
Nov, 2031

(9 years from now)

IN289826B ALLERGAN Piperidinone Carboxamide Azaindane Cgrp Receptor Antagonists
Nov, 2031

(9 years from now)

EP2638042A1 ALLERGAN Piperidinone Carboxamide Azaindane Cgrp Receptor Antagonists
Nov, 2031

(9 years from now)

EP2821407B1 ALLERGAN Piperidinone Carboxamide Azaindane Cgrp Receptor Antagonists
Nov, 2031

(9 years from now)

EP2821407A1 ALLERGAN Piperidinone Carboxamide Azaindane Cgrp Receptor Antagonists
Nov, 2031

(9 years from now)

EP2638042B1 ALLERGAN Piperidinone Carboxamide Azaindane Cgrp Receptor Antagonists
Nov, 2031

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9833448 ALLERGAN Piperidinone carboxamide azaindane CGRP receptor antagonists Nov, 2031

(9 years from now)

US10117836 ALLERGAN Tablet formulation for CGRP active compounds Jan, 2035

(12 years from now)

Drugs and Companies using UBROGEPANT ingredient

Treatment: Acute treatment of migraine with or without aura in adults

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
50MG TABLET;ORAL Prescription
100MG TABLET;ORAL Prescription

24. Drug name - VIIBRYD

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7834020 ALLERGAN Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride
Jun, 2022

(3 months ago)

US8673921 ALLERGAN Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride
Jun, 2022

(3 months ago)

CN100384841C ALLERGAN 1 - [4 - (5-Cyanoindol-3-Group) Butyl] - 4 - (2-Carbamoyl-Benzofuran-5-Yl) - Piperazine Hydrochloride Polymorph
Jun, 2022

(3 months ago)

CN101139345A ALLERGAN Polymorphic Forms Of 1-4-(5-Cyanoindol-3-Group) Butyl-4-(2-Carbamoylbenzofuran-5-Group) Piperazine Hydrochloride
Jun, 2022

(3 months ago)

CN1516699A ALLERGAN 1 - [4 - (5-Cyanoindol-3-Group) Butyl] - 4 - (2-Carbamoyl-Benzofuran-5-Yl) - Piperazine Hydrochloride Polymorph
Jun, 2022

(3 months ago)

CN101139345B ALLERGAN 1 - [4 - (5-Indole-3-Yl) Butyl] - 4 - (2-Carbamoyl-Benzofuran-5-Yl) - Piperazine Hydrochloride Polymorph
Jun, 2022

(3 months ago)

EP1397357B1 ALLERGAN Polymorphic Forms Of 1-[4-(5-Cyanoindol-3-Yl)Butyl]-4-(2-Carbamoylbenzofuran-5-Yl)Piperazine Hydrochloride
Jun, 2022

(3 months ago)

EP1397357A2 ALLERGAN Polymorphic Forms Of 1-[4-(5-Cyanoindol-3-Yl)Butyl]-4-(2-Carbamoylbenzofuran-5-Yl)Piperazine Hydrochloride
Jun, 2022

(3 months ago)

EP1397357B9 ALLERGAN Polymorphic Forms Of 1-[4-(5-Cyanoindol-3-Yl)Butyl]-4-(2-Carbamoylbenzofuran-5-Yl)Piperazine Hydrochloride
Jun, 2022

(3 months ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8236804

(Pediatric)

ALLERGAN Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride Dec, 2022

(2 months from now)

US8193195

(Pediatric)

ALLERGAN Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride Dec, 2022

(2 months from now)

US8673921

(Pediatric)

ALLERGAN Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride Dec, 2022

(2 months from now)

US7834020

(Pediatric)

ALLERGAN Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride Dec, 2022

(2 months from now)

More Information on Dosage
Strength Dosage Availability
10MG TABLET;ORAL Prescription
20MG TABLET;ORAL Prescription
40MG TABLET;ORAL Prescription

25. Drug name - VRAYLAR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7943621 ALLERGAN Salts of piperazine compounds as D3/D2 antagonists
Dec, 2028

(6 years from now)

US7737142 ALLERGAN (Thio) carbamoyl-cyclohexane derivatives as D3/D2 receptor antagonists
Sep, 2029

(6 years from now)

CN1829703B ALLERGAN As A D 3 /D 2 Receptor Antagonist (Thio) Carbamoyl-Cyclohexane Derivatives
May, 2024

(1 year, 7 months from now)

CN1829703A ALLERGAN As D
May, 2024

(1 year, 7 months from now)

CN101679315A ALLERGAN Novel Piperazine Salts As D3/D2 Antagonists
May, 2028

(5 years from now)

CN101679315B ALLERGAN A D <Sub> 3 </Sub> /D <Sub> 2 </Sub> A Piperazine Salt.
May, 2028

(5 years from now)

IN200904256P2 ALLERGAN Novel Piperazine Salts As D3/D2 Antagonists
May, 2028

(5 years from now)

IN293352B ALLERGAN A Process For The Preparation Of Novel Piperazine Salts As D3/D2 Antagonists
May, 2028

(5 years from now)

EP1663996B1 ALLERGAN (Thio)Carbamoyl-Cyclohexane Derivatives As D3/D2 Receptor Antagonists
May, 2024

(1 year, 7 months from now)

EP1663996A1 ALLERGAN (Thio)Carbamoyl-Cyclohexane Derivatives As D3/D2 Receptor Antagonists
May, 2024

(1 year, 7 months from now)

EP2155696A2 ALLERGAN Piperazine Salts As D3/D2 Antagonists
May, 2028

(5 years from now)

EP2155696B1 ALLERGAN Piperazine Salts As D3/D2 Antagonists
May, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE47350 ALLERGAN Pharmaceutical formulations containing dopamine receptor ligands Jul, 2029

(6 years from now)

Drugs and Companies using CARIPRAZINE HYDROCHLORIDE ingredient

Treatment: Treatment of schizophrenia and/or acute manic or mixed episodes associated with bipolar i disorder with cariprazine; treatment of schizophrenia with cariprazine; treatment of acute manic or mixed episodes associated with bipolar i disorder with cariprazine; treatment of depressive episodes associated with bipolar i disorder (bipolar depression) with cariprazine

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 1.5MG BASE CAPSULE;ORAL Prescription
EQ 3MG BASE CAPSULE;ORAL Prescription
EQ 4.5MG BASE CAPSULE;ORAL Prescription
EQ 6MG BASE CAPSULE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.